NP Life Sciences Health Industry Group Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data NP Life Sciences Health Industry Group Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2020
FY2021
FY2022
FY2023
Revenue
0.04
0.02
0.03
0.1
0.16
General and administrative
0.15
0.15
0.1
0.12
0.17
Operating income
-0.11
-0.13
-0.07
-0.02
-0
Interest expense
0
0
Interest income
0
0
0
Other non-operating income
0
-0
Pre-tax income
-0.11
-0.13
-0.07
-0.02
-0
Income tax
0
Net income
-0.11
-0.13
-0.07
-0.02
-0
EPS, basic
0.00
0.00
0.00
0.00
0.00
EPS, diluted
0.00
0.00
0.00
0.00
0.00
Shares, basic (weighted)
34.1
43
43
43
43
Shares, diluted (weighted)
34.1
43
43
43
43
Balance sheet
FY2019
FY2020
FY2021
FY2022
FY2023
Cash and equivalents
0.24
0.12
0.03
0.12
0.07
Other current assets
0.01
0.01
0.01
Intangible assets
0.01
Total assets
0.25
0.12
0.04
0.13
0.08
Accounts payable
0
0.01
0.01
Accrued liabilities
0.01
0.01
0
0
0.03
Deferred revenue
0.1
Total current liabilities
0.11
0.04
Total liabilities
0.02
0.01
0
0.11
0.06
Paid-in capital
0.36
0.36
0.36
0.36
0.36
Retained earnings
-0.13
-0.26
-0.33
-0.35
-0.35
Shareholders' equity
0.23
0.1
0.04
0.02
Total equity
0.23
0.1
0.04
0.02
0.02
Total liabilities and equity
0.25
0.12
0.04
0.13
0.08
Shares outstanding
43
43
43
43
43
Cash flow statement
FY2019
FY2020
FY2021
FY2022
FY2023
Net income
-0.11
-0.13
-0.07
-0.02
-0
Change in payables
0
-0
0.01
Cash from operations
-0
-0.12
-0.09
0.09
-0.07
Cash from investing
-0.01
Debt issued
0.02
Cash from financing
0.36
0.02
Net change in cash
0.24
-0.12
-0.09
0.09
-0.05
Interest paid
0
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use fiscal 2023. Valuation uses the share price of $10.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-0.4%
Operating income / revenue.
Pre-tax margin
-0.8%
Pre-tax income / revenue.
Net margin
-1.8%
Net income / revenue.
Operating cash flow margin
-44.7%
Cash from operations / revenue.
Return on assets (ROA)
-2.9%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
61.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
122.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow growth, 1y
-178.4%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-39.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-13.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
0.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
0.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Quick ratio
1.85x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.85x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
78.7%
Total liabilities / total assets.
Interest coverage
-1.07x
Operating income / interest expense.
Efficiency
Metric
Value
How it is calculated
Asset turnover
1.61x
Revenue / average total assets.
Per share
Metric
Value
How it is calculated
EPS, diluted
$0.00
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
$0.00
Net income per basic share, as reported (split-adjusted).
Market cap + total debt - cash - short-term investments.
P/S
2,610x
Market cap / revenue.
EV/Sales
2,609x
Enterprise value / revenue.
Earnings yield
-0.0%
Net income / market cap (the inverse of P/E).
What was NP Life Sciences Health Industry Group Inc.'s revenue in fiscal 2023?
NP Life Sciences Health Industry Group Inc. reported revenue of $164.6K for fiscal 2023, 61.4% higher than the year before.
Was NP Life Sciences Health Industry Group Inc. profitable in fiscal 2023?
No. It reported a net loss of $2.9K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.